Skip to content
- Select lung cancer patients for personalized chemotherapy based on new molecular profiling-based guidelines
- Outline the clinicaldata supporting the optimal use of epidermal growth factor receptor (EGFR) and EGFR-T790M–inhibitors in the treatment of NSCLC
- Identify strategies to overcome secondary or acquired resistance to EGFR-positive and EGFR-T790M–positive NSCLC
- Outline the clinical data supporting the optimal use of anti-PD-1 and PD-L1 antibodies in the treatment of NSCLC
- Outline the clinical data supporting the optimal use of anti-PD-1, PD-L1 antibodies and combination approaches in the treatment of NSCLC
- Outline the mechanisms of action of PD-1 and PD-L1 blockade in SCCHN with high mutational burden and implication of immune resistance in SCCHN
- Evaluate PD-1/PD-L1 interactions through nivolumab and pembrolizumab that contribute to better outcomes for patients with SCCHN
- Overview of molecular targeted therapy on the outcome of early-stage NSCLC patients with EML4-ALK fusion gene and the application of ALK TKIs
- Identify strategies in the treatment of NSCLC patients with ALK inhibitors
- Identify strategies to overcome secondary or acquired ALK TKI resistance in patients with NSCLC
